Trial Profile
Effectiveness of lixisenatide and dapagliflozin in Nonalcoholic Fatty Liver Disease patients with type 2 diabetes mellitus (T2DM) compared with sitagliptin and pioglitazone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Lixisenatide (Primary) ; Metformin; Pioglitazone; Sitagliptin
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 24 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association